Stallergenes

Stallergenes, Inc.
Public (Euronext: STAGR)
Founded 1962[1]
Headquarters Antony, Hauts-de-Seine, France
Key people
Christian Chavy (Chief Executive Officer)
Revenue Increase 251 million
Website www.stallergenes.com/en.html

Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. Stallergenes has a comprehensive approach of the allergic diseases with a complete portfolio combining diagnosis products and treatments.

Each year, almost 500,000 patients are treated with Stallergenes medicines.

Executive committee

A pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies around the world.

Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.

The second project in this programme is the house dust mite immunotherapy tablet:

Three other projects intended for the treatment of allergic rhinitis caused by birch pollen, Japanese cedar and ragweed pollen are currently under development.

References

This article is issued from Wikipedia - version of the 3/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.